Loading...

Inotiv, Inc.

NOTVNASDAQ
Healthcare
Medical - Diagnostics & Research
$1.89
$0.15(8.62%)

Inotiv, Inc. (NOTV) Financial Performance & Income Statement Overview

Explore the financials of Inotiv, Inc. (NOTV), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
-14.27%
14.27%
Operating Income Growth
-6.07%
6.07%
Net Income Growth
-3.14%
3.14%
Operating Cash Flow Growth
-124.41%
124.41%
Operating Margin
-2.61%
2.61%
Gross Margin
20.56%
20.56%
Net Profit Margin
-15.63%
15.63%
ROE
-49.21%
49.21%
ROIC
-2.11%
2.11%

Inotiv, Inc. (NOTV) Income Statement & Financial Overview

Analyze Inotiv, Inc.’s NOTV earnings with segmented quarterly and yearly financial statement figures.

MetricQ2 2025Q1 2025Q4 2024Q3 2024
Revenue$124.32M$119.88M$130.42M$105.79M
Cost of Revenue$95.33M$94.84M$100.48M$84.70M
Gross Profit$28.99M$25.04M$29.94M$21.08M
Gross Profit Ratio$0.23$0.21$0.23$0.20
R&D Expenses$0.00$0.00$0.00$0.00
SG&A Expenses$22.23M$24.29M$25.63M$21.81M
Operating Expenses$31.93M$40.55M$43.11M$41.83M
Total Costs & Expenses$127.26M$135.38M$143.58M$126.54M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$13.45M$13.84M$12.32M$12.12M
Depreciation & Amortization$13.82M$14.18M$14.59M$14.12M
EBITDA$11.29M-$1.79M$2.87M-$6.71M
EBITDA Ratio$0.09-$0.01$0.02-$0.06
Operating Income-$2.94M-$15.51M-$13.17M-$20.75M
Operating Income Ratio-$0.02-$0.13-$0.10-$0.20
Other Income/Expenses (Net)-$13.04M-$14.30M-$10.88M-$12.20M
Income Before Tax-$15.98M-$29.81M-$24.05M-$32.95M
Income Before Tax Ratio-$0.13-$0.25-$0.18-$0.31
Income Tax Expense$1.11M-$2.18M-$5.15M-$6.86M
Net Income-$14.87M-$27.63M-$18.89M-$26.09M
Net Income Ratio-$0.12-$0.23-$0.14-$0.25
EPS-$0.44-$1.02$3.44-$1.00
Diluted EPS-$0.44-$1.02$3.44-$1.00
Weighted Avg Shares Outstanding$33.99M$27.16M$26.001M$25.99M
Weighted Avg Shares Outstanding (Diluted)$33.99M$27.16M$26.001M$25.99M

Over the last four quarters, Inotiv, Inc. achieved steady financial progress, growing revenue from $105.79M in Q3 2024 to $124.32M in Q2 2025. Gross profit stayed firm with margins at 23% in Q2 2025 versus 20% in Q3 2024. Operating income totaled -$2.94M in Q2 2025, maintaining a -2% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $11.29M. Net income rose to -$14.87M, with EPS at -$0.44. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;